Brainsway (BWAY) Expected to Release Quarterly Earnings on Wednesday

Brainsway (NASDAQ:BWAY) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Brainsway to announce earnings of $0.10 per share and revenue of $16.5420 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 AM ET.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Brainsway Price Performance

Shares of BWAY opened at $15.80 on Wednesday. The firm has a market capitalization of $634.05 million, a P/E ratio of 45.14 and a beta of 1.24. Brainsway has a one year low of $5.70 and a one year high of $17.35. The business has a fifty day moving average of $15.05 and a 200 day moving average of $14.16.

Hedge Funds Weigh In On Brainsway

Several large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its position in shares of Brainsway by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares during the period. Raymond James Financial Inc. bought a new position in Brainsway in the 2nd quarter worth $85,000. UBS Group AG boosted its holdings in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after buying an additional 60,877 shares during the period. Two Sigma Investments LP increased its stake in Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in Brainsway during the third quarter valued at about $107,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BWAY. BTIG Research initiated coverage on Brainsway in a research note on Monday, July 20th. They set a “buy” rating and a $18.00 price target for the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Brainsway in a report on Friday, July 17th. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Finally, New Street Research reissued a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. Based on data from MarketBeat, Brainsway has an average rating of “Buy” and a consensus price target of $15.67.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.